Non-alcoholic fatty liver disease classification: Difference between revisions
Created page with "__NOTOC__ {{Non-alcoholic fatty liver disease}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==Refere..." |
Aditya Ganti (talk | contribs) |
||
(37 intermediate revisions by 5 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Non-alcoholic fatty liver disease}} | {{Non alcoholic fatty liver disease}} | ||
{{CMG}}; {{AE}} {{VKG}} | |||
==Overview== | |||
Non-alcoholic fatty liver (NAFLD) disease may be classified based on clinical presentation into non-alcoholic fatty liver and non-alcoholic steatohepatitis. | |||
==Clinical Classification== | |||
Non-alcoholic fatty liver disease may be classified based on clinical presentation into non-alcoholic fatty liver and non-alcoholic steatohepatitis.<ref name="pmid24661406">{{cite journal| author=Hashimoto E, Tokushige K, Ludwig J| title=Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges. | journal=Hepatol Res | year= 2015 | volume= 45 | issue= 1 | pages= 20-8 | pmid=24661406 | doi=10.1111/hepr.12333 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24661406 }} </ref><ref name="pmid28303724">{{cite journal| author=Cobbina E, Akhlaghi F| title=Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. | journal=Drug Metab Rev | year= 2017 | volume= 49 | issue= 2 | pages= 197-211 | pmid=28303724 | doi=10.1080/03602532.2017.1293683 | pmc=5576152 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28303724 }} </ref><ref name="pmid25763333">{{cite journal| author=Monteiro JM, Monteiro GM, Caroli-Bottino A, Pannain VL| title=Nonalcoholic fatty liver disease: different classifications concordance and relationship between degrees of morphological features and spectrum of the disease. | journal=Anal Cell Pathol (Amst) | year= 2014 | volume= 2014 | issue= | pages= 526979 | pmid=25763333 | doi=10.1155/2014/526979 | pmc=4333905 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25763333 }} </ref> | |||
{| border="1" cellpadding="5" cellspacing="0" align="center" |class="wikitable" | |||
! colspan="2" style="background:#efefef;" |Based on clinical presentation | |||
|- | |||
! style="background:#efefef;" |Non-alcoholic fatty liver | |||
! style="background:#efefef;" |Non-alcoholic steatohepatitis | |||
|- | |||
| | |||
* Benign | |||
| | |||
* Aggressive | |||
|- | |||
| | |||
* Non-progressive | |||
| | |||
* Can progress to [[cirrhosis]] | |||
* Rarely can give rise to [[hepatocellular carcinoma]] | |||
|- | |||
! colspan="2" style="background:#efefef;" |Based on Etiology | |||
|- | |||
| | |||
* Primary NAFLD | |||
| | |||
* If the cause of the liver disease was unknown. | |||
|- | |||
| | |||
* Secondary NAFLD | |||
| | |||
* If the cause of the liver disease is secondary to: | |||
** Surgery for [[morbid obesity]] | |||
** An adverse drug effect | |||
** Conditions such as [[abetalipoproteinemia]] or [[Wilson's disease|Wilson’s disease]] | |||
|} | |||
==Histopathological classification== | |||
Histological classification of NAFLD includes grading and staging. | |||
* Grade: Depending on degree of [[steatosis]] and necro-inflammatory activity | |||
* Stage: Depending on degree of [[fibrosis]]. | |||
===Grading=== | |||
NAFLD activity score is employed for grading steatohepatitis of NASH. NAS represents the sum of scores for [[steatosis]], lobular [[inflammation]], and ballooning.<ref name="pmid28507929">{{cite journal |vauthors=Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J |title=Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies |journal=J Clin Transl Hepatol |volume=5 |issue=1 |pages=67–75 |year=2017 |pmid=28507929 |pmc=5411359 |doi=10.14218/JCTH.2016.00061 |url=}}</ref> | |||
{| border="1" cellpadding="5" cellspacing="0" align="center" |class="wikitable" | |||
! style="background:#efefef;" |Component | |||
! style="background:#efefef;" |Range | |||
! style="background:#efefef;" |Score | |||
|- | |||
| rowspan="4" |Steatosis | |||
|<5% | |||
|0 | |||
|- | |||
|5-33% | |||
|1 | |||
|- | |||
|34-66% | |||
|2 | |||
|- | |||
|>66% | |||
|3 | |||
|- | |||
| rowspan="4" |Lobular Inflammation | |||
|None | |||
|0 | |||
|- | |||
|<2 focci | |||
|1 | |||
|- | |||
|2-4 | |||
|2 | |||
|- | |||
|>4 | |||
|3 | |||
|- | |||
| rowspan="3" |Hepatocyte -Balloning | |||
|None | |||
|0 | |||
|- | |||
|Few ballooned cells | |||
|1 | |||
|- | |||
|Many ballooned cells | |||
|2 | |||
|- | |||
| rowspan="3" style="background:#efefef;" |Interpretation | |||
| style="background:#efefef;" |0-2 | |||
| style="background:#efefef;" |Non-diagnostic | |||
|- | |||
| style="background:#efefef;" |3-4 | |||
| style="background:#efefef;" |Borderline | |||
|- | |||
| style="background:#efefef;" |5-8 | |||
| style="background:#efefef;" |Diagnostic | |||
|} | |||
===Staging=== | |||
Based on the degree of [[fibrosis]] on [[biopsy]] non-alochoic fatty liver disease can be classified into 4 stages. | |||
{| border="1" cellpadding="5" cellspacing="0" align="center" |class="wikitable" | |||
! colspan="2" style="background:#efefef;" |Staging | |||
|- | |||
|Stage 1 | |||
| | |||
Zone 3 [[fibrosis]]<br> | |||
Perisinusoidal [[fibrosis]]<br> | |||
Portal/ periportal [[fibrosis]] | |||
|- | |||
|Stage 2 | |||
|Perisinusoidal and portal/periportal fibrosis | |||
|- | |||
|Stage 3 | |||
|Bridging [[fibrosis]] | |||
|- | |||
|Stage 4 | |||
|[[Cirrhosis]] | |||
|} | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category:Hepatology]] | [[Category:Hepatology]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Needs content]] | |||
{{WS}} | |||
{{WH}} |
Latest revision as of 13:57, 27 December 2017
Non-Alcoholic Fatty Liver Disease Microchapters |
Differentiating Non-Alcoholic Fatty Liver Disease from other Diseases |
---|
Diagnosis |
Treatment |
Case studies |
Non-alcoholic fatty liver disease classification On the Web |
American Roentgen Ray Society Images of Non-alcoholic fatty liver disease classification |
Non-alcoholic fatty liver disease classification in the news |
Directions to Hospitals Treating Non-alcoholic fatty liver disease |
Risk calculators and risk factors for Non-alcoholic fatty liver disease classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]
Overview
Non-alcoholic fatty liver (NAFLD) disease may be classified based on clinical presentation into non-alcoholic fatty liver and non-alcoholic steatohepatitis.
Clinical Classification
Non-alcoholic fatty liver disease may be classified based on clinical presentation into non-alcoholic fatty liver and non-alcoholic steatohepatitis.[1][2][3]
Based on clinical presentation | |
---|---|
Non-alcoholic fatty liver | Non-alcoholic steatohepatitis |
|
|
|
|
Based on Etiology | |
|
|
|
|
Histopathological classification
Histological classification of NAFLD includes grading and staging.
- Grade: Depending on degree of steatosis and necro-inflammatory activity
- Stage: Depending on degree of fibrosis.
Grading
NAFLD activity score is employed for grading steatohepatitis of NASH. NAS represents the sum of scores for steatosis, lobular inflammation, and ballooning.[4]
Component | Range | Score |
---|---|---|
Steatosis | <5% | 0 |
5-33% | 1 | |
34-66% | 2 | |
>66% | 3 | |
Lobular Inflammation | None | 0 |
<2 focci | 1 | |
2-4 | 2 | |
>4 | 3 | |
Hepatocyte -Balloning | None | 0 |
Few ballooned cells | 1 | |
Many ballooned cells | 2 | |
Interpretation | 0-2 | Non-diagnostic |
3-4 | Borderline | |
5-8 | Diagnostic |
Staging
Based on the degree of fibrosis on biopsy non-alochoic fatty liver disease can be classified into 4 stages.
Staging | |
---|---|
Stage 1 |
Zone 3 fibrosis |
Stage 2 | Perisinusoidal and portal/periportal fibrosis |
Stage 3 | Bridging fibrosis |
Stage 4 | Cirrhosis |
References
- ↑ Hashimoto E, Tokushige K, Ludwig J (2015). "Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges". Hepatol Res. 45 (1): 20–8. doi:10.1111/hepr.12333. PMID 24661406.
- ↑ Cobbina E, Akhlaghi F (2017). "Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters". Drug Metab Rev. 49 (2): 197–211. doi:10.1080/03602532.2017.1293683. PMC 5576152. PMID 28303724.
- ↑ Monteiro JM, Monteiro GM, Caroli-Bottino A, Pannain VL (2014). "Nonalcoholic fatty liver disease: different classifications concordance and relationship between degrees of morphological features and spectrum of the disease". Anal Cell Pathol (Amst). 2014: 526979. doi:10.1155/2014/526979. PMC 4333905. PMID 25763333.
- ↑ Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J (2017). "Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies". J Clin Transl Hepatol. 5 (1): 67–75. doi:10.14218/JCTH.2016.00061. PMC 5411359. PMID 28507929.